BRIEF-AstraZeneca Says Nirsevimab Phase III Trial Met Primary Endpoint

AstraZeneca PLC: * ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT

* ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT * ASTRAZENECA - FIRST POTENTIAL PASSIVE IMMUNISATION TO SHOW PROTECTION AGAINST RSV IN GENERAL INFANT POPULATION